ライフサイエンス

経済的空間を広げるという政府のビジョンのもと、経済開発総局は、医療バイオテクノロジーを巨大なポテンシャルを持った分野として位置づけており、高付加価値がもたらされることを期待しています。

モーリシャスには、これから成長していく臨床研究産業があり、拡大の可能性を秘めています。2011年に臨床試験法が導入されたことで、臨床研究が重要視されるようになりました。医療バイオテクノロジー分野の市場規模は23億Rsを超えており、現在、島内には5つの契約研究機関があり、肝炎、糖尿病、HIVなどの様々な疾患に関する試験を実施しています。

モーリシャスの国民は民族多様性に富み、薬物治療歴のない人々が多くいます。 糖尿病、心血管疾患、がん、高血圧などの感染症や生活習慣病がこの地域内の国や一部エリアで広がりを見せており、臨床試験に適した環境となっています。

+ 1000

化粧品および医薬品関連の試験数

25

活動中の 組織数

1275

雇用総数

  • Setting up of a Clinical Research Organization (CRO) /Clinical Research

    There is a rising incidence of cancer, cardiovascular diseases, diabetes and hypertension amongst others in Mauritius. In this regard, the country provides an ideal platform for clinical research.
    Clinical trials (Phase I– Phase IV) are performed in partnership with specialists in the field (gynecologists, diabetologists, cardiologists, dermatologists, etc.). As at date, more than 30 clinical trials have been run on the island.

    Pre-clinical Research

    Proclamation of the Animal Welfare (Experiment on Animals) Act 2017 has opened up the full chain of pharmaceutical research and will enable companies involved in breeding to expand into pre-clinical research in collaboration with biotech companies. The Mauritian cynomolgus macaque, because of its insular habitat exhibits remarkable peculiarities is highly desired by researchers. These primates are known to be virus-free and genetically homogenous, which make them also very effective in pre-clinical research.

    Research Laboratories & Nutraceuticals

    Mauritius has a rich and diverse flora, with more than 670 species of flowering plants of which 315 are endemic. Furthermore, the East African region is already considered as a biodiversity hotspot. This represents a tremendous opportunity for the development of a nutraceutical industry. Pharmaceutical industry per se has failed to grow substantially due to massive R&D investment and non-competitiveness for generic medicine. Nutraceuticals which is basically food additive and wellbeing materials (moringa, Betel, Rodrigues lemon leaves, etc.) can open new avenues of research and product development.
     

    • Accelerated depreciation of 50% in respect of capital expenditure incurred on R&D, that is the investment cost is fully amortised in 2 years
    • A double deduction in respect of qualifying expenditure on R&D directly related to the entity’s trade or business and provided the R&D is carried out in Mauritius.
    • Exemption of registration duty on acquisition of immovable property in the lifesciences sector
    • VAT exemption on construction of medical R&D centers
    • VAT exemption on plants and equipment
    • 8 years tax holiday for companies involved in manufacture of nutraceuticals and pharmaceutical products

Chat with us

Talk to us